The following recommendations were updated by NTAG at their meeting on the 7th September 2021 and are now available on the website:
- Lurasidone (Latuda®) for the treatment of schizophrenia in adults and adolescents aged 13 years and over – updated recommendation recommending use as an option as per criteria specified in recommendation, and also including use in adolescents.
- Daily vs on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer – updated recommendation that once daily oral 5mg tadalafil may be considered as an option for the management of erectile dysfunction following treatment for prostate cancer. Oral 2.5mg tadalafil is not recommended by NTAG for this indication on the basis of cost.
- Buprenorphine prolonged release injection for opioid dependence – new recommendation that an alternative option for the management of opioid dependence after oral methadone and/or oral buprenorphine.
The June 2021 Minutes are now also available on the site.
The work plan of the group has been updated.